Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Blair C. Jackson
CEOBlair C. Jackson
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
7.41B
Market cap7.41B
Price-Earnings ratio
112.94
Price-Earnings ratio112.94
Dividend yield
—
Dividend yield—
Average volume
2.05M
Average volume2.05M
High today
$44.68
High today$44.68
Low today
$43.10
Low today$43.10
Open price
$43.99
Open price$43.99
Volume
1.73M
Volume1.73M
52 Week high
$55.67
52 Week high$55.67
52 Week low
$27.00
52 Week low$27.00

Stock Snapshot

With a market cap of 7.41B, Alkermes(ALKS) trades at $44.18. The stock has a price-to-earnings ratio of 112.94.

On 2026-10-23, Alkermes(ALKS) stock moved within a range of $43.10 to $44.68. With shares now at $44.18, the stock is trading +2.5% above its intraday low and -1.1% below the session's peak.

Trading activity shows a volume of 1.73M, compared to an average daily volume of 2.05M.

Over the past 52 weeks, Alkermes(ALKS) stock has traded between a high of $55.67 and a low of $27.00.

Over the past 52 weeks, Alkermes(ALKS) stock has traded between a high of $55.67 and a low of $27.00.

ALKS News

Simply Wall St 14h
Alkermes Sleep Research Push Keeps Undervalued Narrative In Focus - Simply Wall Street

...

Alkermes Sleep Research Push Keeps Undervalued Narrative In Focus - Simply Wall Street
TipRanks 7d
Alkermes reinstated with a Buy at Truist

Truist reinstated coverage of Alkermes (ALKS) with a Buy rating and $55 price target The company has effectively leveraged its base business to invest in a comp...

Analyst ratings

70%

of 20 ratings
Buy
70%
Hold
25%
Sell
5%

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.